What's in Hangzhou Grand Biologic Pharmaceutical, Inc.'s pipeline?

Hangzhou Grand Biologic Pharmaceutical, Inc. has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Hangzhou Grand Biologic Pharmaceutical, Inc.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/hangzhou-grand-biologic-pharmaceutical-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Hangzhou Grand Biologic Pharmaceutical, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hangzhou Grand Biologic Pharmaceutical, Inc. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
human histaglobulin	human histaglobulin	marketed	Polyclonal immunoglobulin; antihistamine immunoglobulin	Histamine and mast cell stabilization	Immunology; Allergy

Therapeutic area mix

Immunology; Allergy · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Hangzhou Grand Biologic Pharmaceutical, Inc.:

Cite this brief

Drug Landscape (2026). Hangzhou Grand Biologic Pharmaceutical, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hangzhou-grand-biologic-pharmaceutical-inc. Accessed 2026-05-16.